COLUMBUS, Ohio — A longtime leader of cancer research at St. Jude Children’s Research Hospital in Tennessee started this week as director of the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital.
Nationwide wants Peter J. Houghton to aggressively expand its commercialization efforts out of the institute. The hospital is designing new cancer therapies and wants to expand its clinical trials program — a perennial challenge in oncology, which struggles to enroll both adults and children.
Houghton also spearheaded St. Jude’s Pediatric Preclinical Testing Program, which he’ll now bring to Columbus. The program evaluates cutting-edge pediatric cancer treatments and brings them more quickly to clinical trials and treatment.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
He will also be part of Ohio State University’s Comprehensive Cancer Center.
Houghton was chairman of Molecular Pharmacy, director of the Solid Tumor Program Project Grant, and co-leader of the Solid Malignancies Program at St. Jude Children’s Research Hospital.
“He will usher in a new era of outstanding laboratory and clinical research related to childhood cancer. His discoveries will offer hope to children and their families battling this devastating disease,” Dr. John Barnard, president of The Research Institute at Nationwide Children’s Hospital, stated in the press release.
